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INTRODUCTION 
 
 Acute liver failure is a disease whose etiology is enigmatic as in more 
than 50% of the cases the exact cause cannot be found. Even if the etiology 
is known it is not clear how exactly it causes fulminant hepatic failure and 
hence the pathophysiology is exclusive. As both etiology and 
pathophysiology are not clear we are forced to many novel and sometimes 
even experimental modalities of treatment. Inspite of all these, outcome 
could be quite dismal and the prognosis is said to be perplexing. The hall 
mark of this condition are an acute impairment of liver function the 
presence of hepatic encephalopathy and the absence of persisting liver 
disease. As the only definitive treatment is liver transplantation that is not 
freely available in our country the prognosis is very bad1. 
  
Review of literature 
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REVIEW OF LITERATURE 
 
DEFINITION1: 
 Pediatric Acute Liver Failure Study Group (PALFSG) proposed the 
following criteria. 
 Biochemical evidence of liver injury 
 No history of known liver disease 
 Coagulopathy not corrected by administration of Vitamin K 
 INR>1.5 if patient has encephalopathy or >2 if the patient does not 
have encephalopathy. 
 
 Liver failure refers to the clinical stage resulting from hepatocyte 
dysfunction and necrosis. Impairment in liver function is characterized by 
deranged synthesis (coagulation) detoxification and consequent 
encephalopathy. There are a multitude of causative factors which differ 
between children and adults. 
 
 Regardless of antecedent cause the clinical presentation is similar 
mortality is between 60-80% despite adequate care. 
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Acute Liver Failure 
 This term is used for multisystem disorder in which severe 
impairment of liver function INR>1.5 with encephalopathy or INR >2 with 
or without encephalopathy occurs in association with hepatocellular 
necrosis in a patient with no recognized underlying chronic liver disease 
within 8 weeks of initial symptoms. 
 
Acute  Liver Failure 
 This term is used to describe patients without previous liver disease 
who develop a rapidly progressive liver failure within 4 weeks of onset of 
symptoms. 
 
Hyperacute Liver Failure 
 If the features of acute liver failure are evident within one week of 
onset of symptoms it is termed as hyperacute liver failure. 
 
Subacute Liver Failure 
 When the features of acute liver failure are gradual over four weeks to 
12 weeks after and of symptoms and is associated with persistent icterus, 
ascites and or encephalopathy. 
 
 The survival appears to be inversely related to the duration of illness 
survival with hyper acute liver failure is 36%, subacute liver failure is 14% 
4 
  
 
Etiology2 
 The etiology of acute liver failure differs from that described in adults 
and also varies with age in the pediatric population causes also vary across 
geographic regions and countries. In developing countries where hepatitis A 
or E are endemic these will be the most common causes of fulminant 
hepatic failure. 
 
1. Infections 
a) Viral Infections 
Hepato tropic viruses A-G 
Other viruses like Dengue, Epstein Barr Virus, Ebola Virus around 
Virus herpes virus. 
 
b) Bacterial infections 
a. Enteric fever 
b. E.coli septicemia 
c. Meningococaemia 
d. Weil’s disease 
e. Congenital syphilis 
c) Protozoa infection 
a. Falciparum malaria 
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2. Metabolic causes 
 Wilsons disease 
 Galactosemia 
 Hereditary  hemochromatosis 
 Hereditary fructose intolerance 
 Iron storage disease 
 Fatty and oxidation defects 
 
3. Drugs 
 INH 
 Paracetamol 
 NSIADS 
 Valproate 
 Carbamazepine 
 
4. Toxins 
 Aflatoxins 
 Amantia phalloides 
 Carbon tetrachloride 
 Iron 
 
5. Congestive causes 
 Congenital, cyanotic heart disease 
 Congestive cardiac failure 
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 Circulatory shock 
 Myocarditis 
 Budd Chiari Syndrome 
 
6. Miscellaneous 
 The most common cause of FHF in children is viral hepatitis. 0.1% of 
patients with hepatitis A and 1% with hepatitis B develop FHF. The 
prevalence of hepatitis A in FHF varies from 1 to 30% and that of hepatitis 
B from 25 to 75%.2 
 
Acute Viral Hepatitis 
 Acute hepatitis refers to an inflammatory disorder of the liver which 
is usually associated with a complete clinical and histological recovery 
within a period of 4 to 6 weeks in children it is most commonly caused by 
hepatotropic viruses followed by drugs and metabolic liver disease and 
rarely autoimmune liver disease. Acute viral hepatitis is usually self limited 
mild disease which does not require any active treatment. However it may 
sometimes lead on to fulminant hepatitis that may require liver 
transplantation. 
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Etiology: 
1. Hepatotropic Viruses 
 Hepatitis A – type 72 entero virus 
Hepatitis B – hepadna virus 
Hepatitis C – flavi virus 
Hepatitis D – satellite virus 
Hepatitis E – calci virus 
Hepatitis G – flavi virus 
Transfusion transmitted virus – DNA virus 
 
2. Non hepatotropic viruses 
Dengue 
 Mumps 
Measles 
Rubella 
Echo 
Coxsackie B 
Epstein virus 
 
3. Exotic Viruses 
 Marburg virus 
Ebola virus 
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PATHOLOGY3 
 The basic pathology of all types of viral hepatitis is similar. There is 
an acute inflammation of the entire liver characterized by hepatocellular 
necrosis and infiltration with leucocytes and histiocytes. The necrosis is 
maximum in Zone III and greatest cellularity is seen in portal tracts. The 
sinusoids show infiltration with mononuclear cells polymorphs and 
eosinophils. The surviving hepatocytes stain their glycogen. Zone III 
hepatocytes show eosinophils change (acidophil bodies). The reticular 
framework is well preserved inflammatory cells disappear gradually as the 
patient recovers. Occasionally the patient may develop confluent or sub 
massive necrosis affecting substantial groups of adjacent hepatocytes 
usually in Zone III. If the patient develops fulminant hepatitis there is 
massive hepatocellular necrosis involving the whole acinus. The liver is 
shrunken macroscopically and the prognosis is very bad. 
 
Hepatitis A: 
 It is an ancient disease described first by Hippocrates in 44BC. It is 
caused by type 72 enterovirus which was named hepatitis A by Mac calum 
in 1947. It is the most common cause of hepatitis in children. It is relatively 
benign disease. The incidence of fulminant hepatitis being only <0.1%. 
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Hepatitis B :  
 Hepatitis B is a partially double standard DNA virus that belongs to 
hepadna virus. It has a complete coding strand paired with an incomplete 
and noncoding strand. The virion of hepatitis B (Dane Particle) consists of 
surface and core. The core is formed in the hepatocyte nucleus and the 
surface particles in the cytoplasm. The core contains the following 
 
 Genome of HBV which is partially double stranded DNA 
 DNA Polymerase 
 HBcAg 
 HBeAg 
The incidence of fulminant hepatitis about 1%.4 
 
Hepatitis D: 
 It is caused by small defective RNA virus related to plant satellite 
virus. It is not able to replicate on its own, but is capable of infection when 
activated by the presence of hepatitis B virus. The interaction between two 
viruses is complex. Synthesis of delta virus may depress the appearance of 
Hepatitis B viral markers in the infected cells and may even lead to elements 
of active Hepatitis B viral replication. 30% of fulminant hepatitis B may be 
due to coincidental delta infection. 
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Hepatitis C: 
 HCV is a single stranded enveloped RNA virus. It belongs to flavi 
virus family. It is responsible for 90% of post transfusion hepatitis in the 
world and is also an important cause of sporadic non A – non B hepatitis. 
The incubation period is 60-90 days. It is usually a mild disease 75% being 
anicteric and completely asymptomatic. 
 
Hepatitis E: 
 Hepatitis E is a small RNA virus non enveloped and icosahedral 
caused by calcivirus. Acute icteric hepatitis is the commonest type. The 
clinical features are similar to those of Hepatitis A. It is insidious in onset. 
 
METABOLIC CAUSES 
Wilson Disease 
 It is a rare autosomal recessive disease characterized by a toxic 
accumulation of copper in lower brain cornea, skeletal system and other 
tissues. It is an important cause of chronic liver disease and fulminant 
hepatitis in children. The abnormal gene for Wilson disease is on long arm 
of chromosome 13 codes for ATP7B encode copper transparently p-type 
ATPases. The average intake of copper in breast fed babies is 50ug/day and 
in older adults 1mg/day of this 50% is unabsorbed and passed in the stools 
and 30% is lost through the skin. The remaining 20% is absorbed within 
enterocytes by metallothionein which is cystein rich protein. Copper is then 
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exported from the enterocyte to the portal blood by the menkes protein. 
Absence of this protein causes accumulation of copper within the 
enterocytes failure of absorption and systemic copper deficiency. Acute 
fulminant hepatitis is characterized by progressive jaundice ascites and renal 
failure usually in a child or young person. Acute intravascular hemolysis 
may be due to destruction of erythrocytes by sudden release of copper from 
necrotic lymphocytes5. 
 
Heriditary Tyrosinaemia 
 The clinical presentation varies from fulminant hepatic failure to poor 
weight gain and renal tubular acidosis. They may also present with E.coli 
septicaemia and multiorgan failure. Galactosaemia, hereditary fructose 
intolerance type I tyrosinaemia and neonatal hemochromatosis may present 
as fulminant hepatic failure in neonates and infants. Disorders of fatty acid 
oxidation and of oxidative phosphorylation cause recurrent hepatic 
dysfunction and coma which may be confused with Reye syndrome. 
 
DRUGS 
 These are the most important causes of fulminant hepatic failure after 
viral hepatitis. They are fulminant hepatic failure as a consequence of either 
a dose dependent toxic injury or more commonly as an idiosyncratic 
reaction of therapeutic doses. 
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 Most drugs are water insoluble and hence cannot be excreted by the 
liver or kidney. In the liver these are converted to water soluble products so 
that they can be excreted easily in urine or bile. Genetic polymorphisms of 
proteins that biotransform and excrete xenobiotics may increase the 
production of potentially hepatotoxic metabolites. The mechanisms of drug 
induced liver injury include; 
 Disrupted cell membrane 
 Altered cannalicular function 
 Formation of reactive intermediates 
 Immune mediated injury 
 Kupffer cell activation 
 Stellate cell activation 
 Mitochondrial dysfunction 
 Endothelial injury 
 
 Synergistic injury from multiple drug exposures is emerging as a 
frequent cause of fulminant hepatic failure. Here single drug exposure is 
nontoxic but the combination compromises the ability of the liver to clear 
potentially toxic metabolites. 
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Paracetamol 
 Paracetamol injures the hepatocyte in a dose dependent manner. It 
accounts for more than 50% of cases in adults in the west. It usually occurs 
within 48 hours of an intentional overdose 95% of paracetamol is 
conjugated to sulphate and glucuronide and excreted in urine. With the 
ingestion of a massive dose the pathway is overwhelmed. Paracetamol is 
now converted to N-acetyl P-benzoquinone urine (NAPq1) by cytochrome 
P450 system. NAPQI is detoxified by conjugation with glutathione. With 
depletion of glutathione stored in the liver NAPQI binds to the cysteine 
groups of protein forming hepatotoxic protein adults.5 
 
 Paracetamol induced acute liver failure is usually due to single acute  
ingestions. It may also be due to chronic use of paracetamol with therapeutic  
intent. The concentration of paracetamol suspensions in our country varies  
considerably from 100mg/5ml to 250mg/5ml of a quack who does not 
realize this and a common cause of drug induced liver failure. One teaspoon 
QID of a preparation  containing 250mg/5ml for one week he could develop 
acute liver failure. 
 
 SGPT levels will be very high exceeding 3500IU/L. In a patient with 
very  high levels of SGPT out of proportion to jaundice paracetamol toxicity  
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should be considered as a cause even when historic evidence is lacking. 
Measurement of serum paracetamol well predicts the risk of acute liver  
failure only in acute over dosage. In contrast plasma levels are not reliable 
 in chronic overdose or in the presence of other risk factors like fasting or  
concurrent therapy with Cyp 2E1 inducing agents. In the latter situations the 
 diagnosis and treatment are dependent on historical and clinical laboratory 
 findings. 
 
Anticonvulsants: 
 Phenytoin, carbamazepine, valproic acid and phenobarbitone may 
cause acute liver failure. Liver injury occurs within 6 weeks of exposure and 
is almost always accompanied by severe rash and eosinophilia indicating an 
immune mediated injury. Phenytoin is metabolized to a highly reactive 
intermediate by cytochrome P450 system. Neoantigens develop if the 
reactive metabolic binds covalently to tissue macromolecules and antigen 
precipitate immune mediated injury6. 
 
Anti TB Drugs 
 Tuberculosis is quite common in our country and hence many 
children receive anti-TB treatment, 1% children recovery INH may develop 
acute hepatitis which may progress to acute liver failure. 
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TOXINS: 
 Acute liver failure could result following the ingestion of poisonous 
mushrooms like Amantia phalloides and Amantia verna. They contain 
phalloidin and amanitiatoxin which are highly hepatotoxic. The fatal dose is 
present in just 3 mushrooms  
 
Ischaemic Hepatitis 
 This is characterized by centrilobular necrosis with preservation of 
the peripheral zone ,Serum AST may reach 5000 to 10000 IU/L and 
coagulopathy may be found in 25-50%. AST levels rapidly decrease in 
response to stabilization of circulation. The rapid decline in AST levels in 
the absence of increasing serum bilirubin or worsening coagulopathy may 
distinguish ischemic hepatitis from renal or toxic hepatitis. Prognosis 
depends upon correction of underlying cause of hepatitis. 
 
Autoimmune Hepatitis 
 Autoimmune hepatitis can present as acute liver failure in children 
and is an example of immune dysregulation. Autoimmune hepatitis should 
always be ruled out as treatment with steroid may permit survival without 
liver transplantation. Autoimmune hepatitis occurs due to an immune 
reaction to liver allo antigens. With the acute presentation autoantibodies 
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may be absent and liver histology shows severe hepatic necrosis 
accompanied by interface hepatitis and plasma well infiltrates7. 
 
Etiology According to Age  
Neonates and Infants 
 Septicemia 
 Inborn errors of metabolism 
 Tyrosinemia 
 Galactosemia 
 Hereditary fructose intolerance 
 Mitochondrial disorders 
 Severe birth asphyxia 
 Perinatal herpes simplex infection 
 Hemophagocytic lymphohistiocytosis 
 
Older children 
 Viral Hepatitis A, B, B+D, E 
 Parvovirus, Adenovirus 
 Herpes simplex 
 Hepatotoxic drugs 
 Shock, ischemic hepatitis 
 Hematological malignancy 
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 Hodgkin’s lymphoma 
 Leukemic infiltrates 
 Autoimmune hepatitis type 2 
 Wilson disease 
 Inborn errors of metabolism 
 Infusions 
 Industrial poisons 
 
PATHOGENESIS 
Factors that are involved in fulfillment hepatic failure. 
 
1) Injury to hepatocyte plasma membrane 
 The hepatocyte plasma membrane maintains the functional integrity 
of the cell by regulatory fluid ions and macromolecular flexes into and out 
of the hepatocyte. The plasma membrane may be damaged by the immune 
attacks of virus and drugs. This causes loss of electrolytes enzymes and 
coenzyme from the cells and entry of calcium into the cells causing cell 
death. The loss of hepatocyte is an important cause of acute liver failure8. 
 
2) Organelle dysfunction 
 The residual function of the surviving hepatocytes is determined by 
the damage to subcellular organelles. Calcium is responsible for the acute 
liver failure in metabolic diseases like Wilson disease. 
18 
  
 
 Drugs may be activated to toxic metabolites by microsomal enzyme 
system and there is damage to the vital macromolecules of the cells. 
Similarly free radicals may be produced that damage cellular lipids 
and proteins. 
 
 The toxins of Amanita phalloides mushroom may affect the 
endoplasmic reticulum causing acute liver failure. 
 
3) Disturbances of hepatic circulation 
The hepatic circulation is compromised in acute liver failure by two 
features. 
- Portosystemic shunting 
- Impaired sinusoidal micro circulation 
 
 There features deprive the hepatocytes of adequate nutrients so that 
they are not able to remove circulatory toxins. This contributes to acute liver 
failure. 
 
4) Regenerative capacity of liver 
 The final factor in the pathogenesis of acute liver failure is the 
regenerative capacity of the liver. If regeneration is less than degeneration 
acute liver failure results and it is due to the following factors. 
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 If the injurious process is prolonged hepatocellular regeneration is 
affected. 
 Role of hepato trophic factors : Insulin glucagon and epidermal 
growth factor may help in the regeneration of hepatocytes. Hence 
their deficiency will aggravate degeneration9. 
 
Pathophysiology: 
 Acute liver failure is characterized by marked splanchnic and 
systemic arteriolar vasodilation along with hyper dynamic circulation and 
low arteriovenous oxygen content difference. Tissue hypoxia develops 
despite adequate arterial oxygen and this contributes to development of 
multi organ failure and is a marker of post prognosis10. 
 
 Microcirculatory plugging is caused by formation of micro thrombi as 
a consequence of activation and consumption of platelets along with 
the increased adhesion of leucocytes to the endothelial wall. Increased 
activity of CGMP results in vasodilation. 
 
 Encephalopathy results from the accumulation of non metabolized 
ammonia mercaptans fatty acids and GABA. Production of false 
neurotransmission is enhanced due to decreased aromatic and 
branchial chain amino acids in the blood. The cerebral metabolism is 
altered. Renal failure of various degrees occurs in acute liver failure 
20 
  
patients. Hypovolemia caused by vasodilation microcirculatory 
disturbance and acute tubular necrosis are contributing factors. Rapid 
deterioration in the nutritional status with depletion of muscle and fat 
stores often occurs as a consequence of unpaired gluconeogenesis and 
impaired glycogen storage. 
 
 Hypoglycemia hypophosphatemia and hypomagnesemia are common 
metabolic acidosis is relatively frequent due to tissue hypoxia 
increased peripheral lactate production and renal failure. 
 
 Reduced hepatic synthesis of clotting factors increased consumption 
of clotting factors and platelets contribute to the coagulopathy 
associated with acute liver failure. 
 
 Children with acute liver failure are susceptible to infections as a 
consequence of impaired neutrophils and Kupffer cell phagocytic 
function with reduced compliment levels. Induced bacterial changes 
in the gut flora may also contribute to this. The common infections 
that occur are pneumonia, urinary tract infections and spontaneous 
bacterial peritonitis (SPB). A vicious cycle of endotoximia circulatory 
collapse tissue hypoxia, increased bacterial translocation contribute to 
multi organ failure11. 
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PATHOLOGY 
Jones classification of Acute liver failure. 
 Type 1 lesion 
 Type 2 lesion 
 Type 3 lesion 
 
Type 1 lesion 
 This is the most common lesion in acute liver failure and is 
characterized by necrosis and loss of hepatocytes. This is seen in  
 Viral hepatitis 
 Toxic hepatitis  
 Ischemic hepatitis 
 Metabolic hepatitis (Wilson disease, neonatal hemochromatosis) 
 
 The degree and pattern of hepato cellular injury vary according to the 
etiology. However they do not correlate with the development of hepatic 
encephalopathy or cerebral edema. Besides liver biopsy is very risky on the 
patients. Hence establishing a pathological diagnosis is not critical in the 
management of the patient. 
 
 Massive confluent or multi lobular necrosis can be demonstrated at 
autopsy or following orthotopic liver transplantation. 
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 Serum bilirubin varies from 10-60mg%. The damaged hepatocyte can 
take up and conjugate bilirubin initially but cannot excrete it into late as it is 
an energy dependent process thereby resulting in conjugated 
hyperbilirubinemia. However as the damage increases the uptake of 
bilirubin is also affected resulting in increase of unconjugated bilirubin 
also12. 
 
Type 2 lesion 
 This is characterized by the presence of microvascular fatty 
infiltration. The brunt of the damage is on the mitochondria and 
hepatocellular necrosis is insignificant. Hence jaundice is minimal and 
transaminases are only slightly elevated. If the patient survives the 
histologic recovery is complete. This picture is seen. 
 Reye syndrome 
 Valproate toxicity 
 Acute fatty liver of pregnancy13 
 
Type 3 Lesion: 
 This is characterized by swelling of hepatocytes and condensation of 
organelles and cytoplasmic elements spotty hepatocellular necrosis and 
macrovascular fatty infiltration are also seen. Serum bilirubin and 
transaminases are moderately elevated the levels being between those type 1 
and type 2 lesions. This picture is seen in  
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 Hereditary fructose intolerance 
 Type 1 tyrosinaemia 
 
CLINICAL FEATURES 
 Acute liver failure affects previously healthy children with no 
recognized risk factors for liver disease. Children usually present with 
hepatitis and worsening of symptoms over a period of several days or 
weeks. Jaundice is the presenting symptom of most of the children and its 
day of onset should be noted. A prodrome of flu like illness may precede 
jaundice. Fever. Anorexia, vomiting, abdominal pain and fetor hepaticus are 
common. Altered consciousness and mental changes present later. Infants 
initially may present with poor feeding irritability and disturbances in sleep 
rhythm. Hemorrhages diathesis and ascites may develop later. A detailed 
history of mental changes easy bruising seizures decreased urine output 
contact with infections, injections, blood transfusions drug intake and family 
history of Wilson disease or autoimmune disease and should be excluded 
For neonatal and infections presenting with acute liver failure an additional 
history of developmental delay consanguinity prenatal or antenatal 
infections and neonatal death should be sought14.  
 
 The early clinical manifestations of acute liver failure are non specific 
and characterized by anorexia malaise nausea and vomiting. Central nervous 
system manifestations include hepatic encephalopathy and cerebral edema 
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with raised intracranial tension. Hepatic encephalopathy is a result of 
inability of liver to process and excrete endogenous toxins. Raised levels of 
ammonia, GABA, false neurotransmitters and pro inflammatory cytokines 
are implicated in the pathogenesis. Identification of hepatic encephalopathy 
in children can be challenging as in the early stages they present with 
nonspecific findings such as excessive somnolence, reversal of sleep wake 
cycle or behavioural and personality changes15. 
 
 Coagulopathy due to impaired production of coagulation factors 
results in bleeding platelet counts are affected in setting of an infection. The 
patient may manifest with hypoglycemia electrolyte imbalance and 
metabolic acidosis. Infections are common in acute liver failure as immune 
system is dysfunctional and invasive procedures are performed commonly. 
This results in gram positive gram negative and fungal infections. Infection 
may manifest as hypotension disseminated intravascular coagulation 
metabolic acidosis coronary encephalopathy oliguria and azotemia. 
 
Acute liver failure should be suspected when a child with suspected 
hepatitis develops 
- Persistent anorexia 
- Persistent vomiting 
- Deepening jaundice 
- Decreasing liver span 
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- Relapse of initial symptoms 
- Development of ascites 
- Neuropsychiatric changes 16 
 
COMPLICATIONS 
1. Hepatic encephalopathy 
2. Cerebral edema 
3. Coagulopathy 
4. Metabolic complications 
5. Electrolyte disturbances 
6. Renal complications 
7. Infection 
 
 
1. Hepatic encephalopathy 
 Encephalopathy is an essential component for the diagnosis of acute 
liver disease. It is a consequence of hepatocellular failure directly affecting 
the function of the brain. The damaged liver fails to produce appropriate 
amounts of neuro regulatory substances and to eliminate toxins like 
ammonia17. 
 
Neuropathological changes in Hepatic encephalopathy 
 Grossly the brain may be normal but cerebral edema is seen in about 
half of the patients particularly younger patients dying with prolonged deep 
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coma. Microscopically the characteristic changes are seen in astrocytes 
rather than neurons. The astrocytes proliferate and develop prominent nuclei 
margination of chromatin and accumulation of  glycogen. These changes are 
referred to as Alzheimer type 2 astrocytes These changes are found 
particularly in the cerebral cortex and basal ganglia and are related to 
hyperammonemia neurons shows minor alterations. Early astrocyte changes 
are probably reversible in very long standing cases the structural changes 
may be irreversible and the patient unresponsive to treatment. Apart from 
the astrocytic changes there is cortical thinning with loss of neurons in 
cortex basal ganglion and cerebellum demyelination in the pyramidal tract is 
associated with spastic paraplegia in patients with severe liver disease and 
minimal encephalopathy. The permeability of ammonia is increased18.  
 
Clinical Features: 
 Hepatic encephalopathy causes an organic mental reaction associated 
with neurological disturbance. The clinical picture depends upon the nature 
and intensity of the etiological and precipitating factors19 
- Disturbed consciousness with disordered sleep 
- Hypersomnia 
- reversal of sleep rhythm 
- Reduction of spontaneous movements 
- A fixed stare 
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- Apathy 
- Slowness and brevity of response 
- Personality changes 
- Irritability 
- Intellectual deterioration 
- Handwriting deterioration 
- Constructional apraxia 
- Child may micturate and defecate in inappropriate places 
- Speech is slow and slurred 
- Dysphasia 
- Fetor hepaticus: 
 
 Sweetish slightly feculent smell of the breath which is compared to 
that of freshly opened corpse due to the presence of methionine derivatives 
lie methyl mercaptan which are usually metabolized by the liver20. 
 
Asterixis (Flapping tremor) 
 This is the most characteristic neurological abnormality.  It is due to 
impaired inflow of joint and other afferent information to the brainstem 
reticular formation resulting in lapses in posture 21 
 
 It is demonstrated with the patients arms outstretched and fingers 
separated or by hyper extending the wrists with the forearm fixed. There is a 
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rapid flexion extension movement at the metacarpophalangeal and wrist 
joints accompanied by lateral movement of the digits. Sometimes the   neck 
jaw, protruded tongue, retracted mouth and highly dosed eyelids are 
involved and gait is ataxic. It disappears when patient becomes comatose. It 
is usually bilateral but asymmetric and is absent in coma. It is not specific 
for hepatic precoma and is also seen in renal failure, respiratory failure and 
congestive cardiac failure. Deep tendon reflexes are exaggerated hypertonia 
and ankle clonus may be seen. When comatose deep tendon reflexes are lost 
and flaccidity is seen. Plantar reflexes initially flexor and becomes extented 
in deep coma21. 
 
Factors that contribute to Hepatic encephalopathy 
 Hypoglycemia 
 Hypoxia  
 Haemorrhage 
 Septicemia 
 Hepatotoxic drugs 
 Hypokalemia 
 Reduced cerebral perfusion 
 Cerebral edema22 
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Clinical grading of Hepatic encephalopathy 
Grade 1 :  Confused altered mood or behaviour psychomotor defects  
  no flap. 
Grade 2 :  Drowsy inappropriate behavior flap+ 
Grade 3 :  Stuporous speaks and obeys simple commands 
Grade 4A : Marked confusion coma responds to painful stimuli 
Grade 4B :  Deep coma no response to even painful stimuli 
 
PATHOGENESIS OF HEPATIC ENCEPHALOPATHY 
 Porta systemic shunting 
 Alterations in the blood brain barrier 
 Toxic metabolite affecting the CNS23 
 
Portal systemic shunting 
 In hepatic encephalopathy the various toxic metabolites in the blood 
reach the brain directly without being detoxified by the liver. In fulminant 
hepatitis the shunt in through the liver itself. The damaged hepatocytes are 
not able to remove the toxic products in portal venous blood. Hence they 
pass unaltered into the hepatic veins and subsequently reach the brain. In 
patients with chronic liver disease like cirrhosis the portal blood bypasses 
the liver through large natural collaterals24. 
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 Ammonia is believed to play a major role in pathogens of hepatic 
encephalopathy by the following mechanisms. 
 
 It combines with alpha – ketoglutarate to form glutamic acid thus 
removing an important link in te krebs citric acid cycle which is vital 
for brain metabolism. 
 It has direct toxic effect on the neuronal membrane. 
 It causes an indirect neuronal dysfunction due to disturbance of 
glutamate neurotransmission25. 
 
GABA and endogenous benzodiazepenes: 
 GABA is the principle inhibitory neurotransmitter in the brain. It is 
usually synthesized from glutamate by glutamate dehydrogenase in 
presynaptic nerves and stores and stored in vesicles. GABA binds to 
specific GABA receptor in the postsynaptic  membrane. This receptor is 
part of a larger receptor complex which also has binding sites for 
benzodiazepines and barbiturates The binding of any of the ligand opens a 
chloride channel and after the influx of chloride there is hyperpolarization of 
the postsynaptic membrane and neuro inhibition26. 
 
 GABA is also synthesized by gut bacteria and they entity the portal 
vein is metabolized by the liver. In the presence of liver failure or poor 
portal systemic shunting it enters the systemic circulation. There are 
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increased GABA levels in the plasma of patients with liver disease and 
hepatic encephalopathy27. 
 
 Endogenous benzodiazepines are increased in patients with hepatic 
encephalopathy and these may also interact with the GABA receptor 
complex and cause neuro inhibition. The relationship between plasma 
endogenous benzodiazepines and encephalopathy is however controversial. 
However both central benzodiazepine receptors and peripheral type 
benzodiazepine receptors are increased in the brain in hepatic 
encephalopathy28. 
 
False Neurotransmitter 
The following false neurotransmitter are produced in the colon by bacteria. 
 Tyramine 
 Octopamine 
 Beta Phenylethanolamine 
 
 There reach the brain and inhibit the true transmitter likely to hepatic 
encephalopathy. 
 
Role of Branched chain amino acids and aromatic amino acids 
 The serum level of the aromatic amino acids like tyrosine. 
Tryptophan and phenylalanine are increased due to poor hepatic 
deamination. At the same time well of branched chain aminoacids like 
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valine isolated and leucine are decreased due to increased metabolism by 
skeletal muscle and kidneys secondary to the hyperinsulinemia of chronic 
liver disease29. 
 
 These two groups of amino acids compete for uptake in to the brain. 
As their serum level is higher, more of aromatic aminoacids pass an 
abnormal blood brain barrier into the brain. Phenylalanine in the brain  is 
converted into false neurotransmitter like octopamine and 
phenylethanolamine which may contribute to hepatic encephalopathy. 
 
Stages of Hepatic encephalopathy 
Stage 1 (Prodrome) 
 Personality changes 
 Euphoria 
 Child like behavior in adults infantile behavior in children 
 Sleep disturbances reversal of sleep rhythm and insomnia 
 Intellectual deterioration 
 Inappropriate behavior bursts of anger and crying 
 High pitched ear piercing screams 
 Asterixis may be present 
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Stage 2 HE (impending coma) 
 Accentuation of Stage 2 
 Drowsiness 
 Inappropriate behavior 
 Hyperreflexia 
 Incontinence 
 Marked asterixis 
 EEG abnormalities30 
 
Stage 3 HE (Stupor) 
 Depending somnolence and stupor 
 Patient responds vigorous physical stimuli but goes back to sleep 
immediately 
 Extreme agitation biting and rage 
 
Stage 4 HE (Coma) 
 4A - Patient is comatose but responds to painful stroke 
 4B - Deep coma 
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2. CEREBRAL OEDEMA 
 This is the most common cause of death in acute liver failure. It 
usually occurs in stage 4 hepatic encephalopathy after a prolonged duration 
of coma. However at may present within 24 hours of onset of coma31. 
  
 Sun in 80% of fata cases 
 Grade III, IV encephalopathy 
 Raised head end 45’ 
 Fluid restriction IV mannitol 
 Avoid hyperthermia 
 Ventilate of hepatic encephalopathy > grade III 
 
Pathogenesis 
 Increased permeability of blood brain barrier 
 Inhibition of Na- K+ ATP ase pump 
 Failure of autoregulation of cerebral blood flow 
 Mechanical Ventilation 
 
 It manifests as unequal or abnormality reacting pupils mild clonus or 
seizures and loss of brainstem reflexes. There may be alteration of 
respiratory bradycardia and hypertension50. 
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Clinical features of cerebral edema 
 Increased muscle tone in the limbs 
 Trismus 
 Opisthotonus 
 Decerebrate posturing 
 Hyperventilation 
 Pupils dilated and reacting poorly light 
 
3-COAGULOPATHY 
 A hemorrhage diathesis is invariable in acute liver failure as the liver 
plays a central role in hemostasis32. The following factors contribute to the 
 Failure of synthesis of clotting factors and fibrinolytic factors by the 
damaged liver33. 
 Disturbances in the number and function of platelets 
 A low grade DIC which is common on acute liver failure also 
contributes to coagulopathy34. 
 
 All the clotting factors are synthesized in the liver. Hence the 
prothrombin time and partial thromboplastin time are prolonged35. 
  
36 
  
Coagulopathy may be classified into 
 Mild  PT < 18 
 Moderate PT 18-25 
 Severe PT >2536 
  
Thrombocytopenia is seen in 50% of patients it is caused by  
 Hypersplenism 
 Bone marrow suppression 
 Increased consumption of platelets37 
 
Common types of bleeding 
 Bleeding from puncture sites 
 Upper GI bleed 
 Intracranial bleed38 
 
4. Metabolic Complications 
Hypoglycemia caused by 
 Massive hepatocellular necrosis which impairs glyoneogenesis and 
causes glycogen depletion 
 Diminished hepatic catabolism of insulin by the damaged liver. 
 Increased glucose utilization due to anaerobic metabolism 
 Secondary bacterial infection39 
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5.  Electrolyte disturbances 
Hypokalemia 
 This is due to inadequate replacement increased loss and secondary 
hyperaldosteronism. It may worsen coma and precipitate cardiac 
arrhythmias40. 
 
Hyponatremia 
 The total body sodium is elevated because of secondary 
hyperaldosteronism inhibition of Na- K+ pump also contributes. 
Acid base imbalance 
Respiratory alkalosis – Hyperventilation in early hepatic encephalopathy 
Metabolic alkalosis – frusemide  hypokalemia 
Respiraory acidosis 
 Respiratory failure 
 Cerebral edema 
 Obstructed ET tube 
 Pneumonia 
Metabolic acidosis 
 Metabolic failure – accumulation of organic acids 
 Hypotension poor perfusion lactic acidosis 
 Renal failure  
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 Mechanical ventilation 
 Citrated blood41 
 
6. Renal Complications 
a) Hepato renal syndrome: 
 The functional renal failure is the most common cause of renal failure 
in ALF. It is characterized by 
 Normal urine sediment 
 Marked sodium rectum – urine sodium <20 
 Reduced urine output 
b) Acute tubular necrosis: 
 This is due to hypotension sepsis of hemorrhage complicating ALF. It 
is characterized by 
 Abnormal urine sediment 
 Urine sodium >20mEq/L 
 Severe Oliguria (outpu <0.5 l 
 
c) Prerenal failure : 
 This may be due to dehydration or GI bleeding42 
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7. Infection 
Septicemia is common and is due to 
 Neutropenia 
 Impaired cell mediated and humoral immunity 
 Defective opsonization43 
 Impaired kupffer cell function 
 Frequent  venipuncture  and  catheters44 
 
INVESTIGATIONS 
Infections : IgM anti HAV 
  IgM anti HEV 
 Hepatitis B surface antigen 
IgM anti Hepatitis B core antigen 
CMV – PCR (CMV) 
IgM  VZV (Varicella zoster virus) 
IgM Viral Capsid Antigen (EBV45 
 
Metabolic  
Wilson disease  - Cereoplasmin Kayser fluscher ring 
     24 hours urinary copper 
Autoimmune hepatitis  -       Anti liver kidney microsomal antibody 
                                       Antinuclear antibody 
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                                       Anti smooth muscle antibody46 
                                       Immunoglobulin levels 
Tyrosenemia  - Urinary sucinylactone levels 
Galacosemia  -         Urine nonglycose reducing substances 
     Galactose  1 phosphate uridyl transferase 
Miscellaeous 
Hemophagocytosis - Triglyceride, ferritin, fibrinogen and  
     Bone marrow biopsy 
Paracetamol poisoning - Plasma levels of paracetamol 
 
 Platelet count is reduced due to consumption or reduced production. 
WBC count may be very high due to stress response or associated bacterial 
infection or low due to aplastic anemia47. 
 
 ALT and AST are very high or their levels have fallen suddenly since 
their last measurement. 
 Prothrombin time is very much prolonged 
 Serum bilirubin may be very high 
 Blood ammonia is elevated 28 hours above normal 
 Blood urea nitrogen is high due to renal dysfunction increased 
production of urea secondary to LI bleeding and dehydration. Some 
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times blood urea may be low due to decreased production by Krebs 
urea cycle in the liver. 
 Arterial blood gas analysis shows a wide spectrum of abnormalities 
from respiratory alkalosis to mixed respiratory and metabolic 
acidosis48. 
 
MANAGEMENT 
The management of liver failure in children is based on; 
i) Diagnosis of etiology as it influences the prognosis and 
management. 
ii) Assessment of severity of liver failure and timely liver 
transplantation if indicated49. 
iii) Anticipation prevention and treatment of complications. 
 
General Measures 
- All secretions of the patient should be treated potentially infected 
capable of transmitting hepatitis. 
- Sedatives should be awarded as far as possible  
- Venous access is essential 
- Urinary bladder should be catheterised and fluid intake and output 
chart maintained50. 
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Management of coagulopathy 
 Vitamin K 0.2-0.3mg/kg max 10mg 
 Mild coagulopathy – No treatment 
 Moderate : FFP 10ml/1g 6 hourly to reduce PT 16-18 seconds 
 Severe : FFP 15-20ml/1g 6 hourly to reduce PT to 18-25 
 Cryoprecipitate platelet transfusion51 
 Ranitidine 1-2mg/kg/dose IV 2-4 times / day 
 Omeprazole 0.5 mg/kg/dose NG 1-2 times / day 
 Sucralfate 10-20mg/kg/dose NG 4-6 hourly 
 Administration of recombinant factors VIIa produces temporary 
correction of coagulopathy. 
 Sodium should be restricted to 1mEq/kg/day 
 Hypokalemia should be avoided by giving 3-6mEq/kg/day 
 Anemia should be corrected and Hemoglobin maintained around 
12gms52. 
 
Treatment of cerebral edema 
 Cerebral edema should be treated with 20% mannitol 1g/kg every 2-6 
hours. 
 Fluid restriction less than 75% maintenance 
 Serum osmolality should be maintained below 320 on osm/L 
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 Elective ventilation should be done of cerebral edema suspected 53 
 Steroids should not be used. 
 Convulsion should be controlled with phenytoin or phenobarbitione  
 Cerebral perfusion pressure should be maintained by administration 
of blood products albumin and ionotropic agents 
 Persistent convulsions indicated a grave prognosis54. 
 
Fluid Balance 
 Intake output chart should be maintained 
 The ideal maintenance fluid is 10% dextrose  in 0.25% saline 
 Fluid intake should be <75% maintenance55. 
 
Sodium 
 Total intake should be restricted to 1mEq/kg/day 
 
Potassium 
 Potassium requirements are quite high 3-6mEq/kg/day56 
 
Management of Renal Failure 
 The circulating volume should be maintained to prevent prerenal 
failure. 
 The urine output should be >0.5m/kg/hr 
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 If the CVP is high frusemide . may be given in the dose of 1-
2mg/kg/iv 
 Renal failure usually become normal after a successful liver 
transplantation57. 
 
Hypoglycemia 
 Blood glucose should be monitored every 2-4 hourly 10-50% glucose 
IV will help to prevent e complication58. 
 
Cardiovascular complications 
 Hypotension is common due to reduced peripheral vascular resistance 
arteriovenous shunting. It may be refractory to volume replacement and 
pressure agents59. 
 
Secondary infections 
 Septicemia is seen in 50% of children with acute liver failure. It is 
usually caused by gram positive bacteria like staphylococcus aureus and 
streptococci. Gram negative bacteria and fungi may also be responsible60. 
 
 Broad spectrum antibiotics should be started at the earliest suspicion 
of sepsis. 
 Tachycardia 
 Hypotension 
 Oliguria 
45 
  
 Hypoglycemia 
 Hypothermia 
 Deterioration in mental state 
 
 Amoxicillin 75mg/kg/day in 3 doses; cefuroxime 60mg/kg/day in 3 
doses in metronidazole of there is suspicion of anaerobic infusion 
prophylactic antifungals may also be given61. 
 
Specific therapy for acute liver failure 
 
Paracetamol ingestion 
 N.acetyl cysteine should be started within 24 hours of ingestion and 
continued until liver failure has resolved62. 
 
Fulminant hepatitis B 
 In these patients lamivudine  telbivudine or entecavir is indicated. 
 
Amanita  phalloides poisoning 
 Massive dose of benzylpenicillin may decrease the uptake of 
amatoxin thiotic acid (300mg/kg/day) IG infection may reduce hepatic 
damage63. 
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 The following drugs and procedures have been tried to support the 
liver while awaiting regeneration or transplantation  
 Prostaglandin E 
 Glucagon 
 L-Dopamine 
 Benzodiazepine receptor antagonists like flumazenil 
 Exchange transfusion 
 Plasmapheresis64 
 MARS 
 
 MARS or Molecular absorbent reticulating system is cell free non 
biological artificial liver support system removes albumin bound toxins 
from the blood65. 
 
Extracorporeal Bio artificial liver support devices 
 Extracorporeal systems that combine hepatocytes in a plastic 
cartridge and simplex mobile membrane66 
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Liver transplantation 
 It is the only definitive treatment of acute liver failure, O’Grady’s 
criteria for liver transplantation67 
 
A. Paracetamol induced ALF 
 pH <7.3 
 PT >100 seconds 
 Serum creatinine >300 mmol/L 
 
B. Non Paracetamol induced ALF 
 PT >100 seconds 
 or 
 Any three 
o PT >50 seconds 
o Age <10 years 
o Serum bilirubin >17.5mg% 
o Etiology NANB hepatitis idiopathic drug reactions 
o Duration of jaundice 7 days before the onset of hepatic 
encephalopathy68 
 
It is indicated in all children 
o Stage 3 or 4 HE 
o Viral hepatitis 
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o Paracetamol overdue 
o Halothane hepatitis 
o Wilson disease 
o Type I tyroienemia69 
 
PROGNOSIS 
 Prognosis is good in the following; 
 Age : Children >10 years 
 Hepatitis A 
 Paracetamol poisoning if treated in time 
Presence of an obvious etiology 
Stage of Hepatic encephalopathy in 1 and 2 
Increased serum alpha fetoprotein69 
 
Causes of Death 
 Cerebral edema 
 Overwhelming bacterial or fungal infection 
 Respiratory failure 
 Hemorrhagic diathesis 
 Complication of liver transplantation69 
  
Aims and objectives 
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AIMS & OBJECTIVE  
 
 The aim of my study is to study and determine the clinical profile, 
etiology of acute liver failure in children between 1mon-12yrs  of age in 
tertiary pediatric centre in south india 
 
  
Materials and methods 
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METHODOLOGY 
(MATERIALS & METHODS) 
 
STUDY DESIGN:   
 Prospective study 
 
STUDY POPULATION:  
 Children in study age group attending  gastroenterology department  
and admitted in medical ward  satisfying the inclusion criteria. 
 
PLACE OF STUDY:  
 Department of Gastroenterology and Paediatric medical ward in ICH 
 
STUDY PERIOD :   
  October2016 to june 2017 
 
SAMPLE SIZE : 50 
 
INCLUSION CRITERIA:   
 All children aged 1 month to 12years presenting  with acute liver 
failure  attending the hospital  
 
EXCLUSION CRITERIA:  
 Children with pre-existing liver disease 
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PROCEDURE  
 After obtaining informed consent from parent/guardian, various  
Patient demographic characteristics, history ,clinical  details will be entered 
in a prestructured profoma. All these  children will have basic investigations 
like LFT Serum albumin total proteins liver enzymes viral markers, 
coagulation profile. 
         
STATISTICAL ANALYSIS: 
 Statistical analysis of data will be performed by statistical software 
SPSS. Outcome variables will  be categorized as normal or abnormal and 
their prevalence will be expressed  as percentage and p value of <0.05 will 
be considered significant. 
  
Results 
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OBSERVATION & RESULTS 
 
Age group 
<1 year 11(22%) 
1-5 years 18(36%) 
6-12 years 21(42%) 
 
 
 
 
 
 In this study, 42% of the children belong to 6-12 years, 36% belong 
to 1-5 years and 22% belong to <1 year group. 
  
22%
36%
42%
AGE DISTRIBUTION
<1 YEAR
1-5 YEARS
6-12 YEARS
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SEX DISTRIBUTION 
 
In this study, 30(60%) of the children are females and 20(40%) are males. 
 
SEX NUMBER 
Male 20(40%) 
Female 30(60%) 
 
 
 
  
 
 
  
21%
79%
SEX DISTRIBUTION
MALE FEMALE
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SEX DISTRIBUTION IN CHILDREN <1 YEAR 
 
 
SEX NUMBER 
MALE 6(54%) 
FEMALE 5(46%) 
 
 
 
 
 
 
  
54%
46%
SEX DISTRIBUTION ON CHILDREN<1 YEAR
MALE
FEMALE
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OUTCOME 
 In this study, out of the 50 children studied, 16(32%) improved and 
34(68%) died. 
 
OUTCOME NUMBER 
Improved 16(32%) 
Death 34(68%) 
 
 
 
 
  
19%
81%
0UTCOME
IMPROVED
DEATH
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Drug induced 15(30%) 
Autoimmune 3(6%) 
Infection 17(34%) 
Metabolic 3(6%) 
Congestive 4(8%) 
Inconclusive 8(16%) 
 
 In this study, the etiology of liver failiure  was found to be 
infection(34%), drug induced(30%), inconclusive(16%), congestive 
causes(8%) 
 
 
  
DRUG INDUCED
AUTOIMMUNE
INFECTIONS
METABOLIC
ETIOLOGY
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DURATION OF ILLNESS NUMBER 
<1 week 39(78%) 
>1 week 11(22%) 
 
 
 In this study the duration of illness was found to be <1 week in (78%) 
and >1 week in (22%) 
 
 
 
  
39
11
<1 WEEK >1 WEEK
DURATION OF ILLNESS
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DURATION OF FEVER NUMBER 
<1 week 43(86%) 
>1 week 7(14%) 
 
 
 In this study, 43(86%) children had fever < 1 week duration and 
7(14%) had fever >1 week duration. 
 
  
<1 WEEK >1 WEEK
43
7
DURATION OF FEVER
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ETIOLOGY AMONG INFECTIOUS CAUSES 
 
INFECTIOUS ETIOLOGY NUMBER 
DENGUE 9(56%) 
HEPATITIS A 3(18.75%) 
LEPTOSPIROSIS 2(12.5%) 
SEPSIS 2(12.5%) 
 
 In this study among the infectious causes dengue contributed 
maximum of 56% while hepatitis A(18.75%) leptospirosis(12.5%) and 
sepsis(12.5%)  
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BLEEDING NUMBER 
Present 16(32%) 
Absent 34(68%) 
 
In this study, 16(32%) had bleeding and 34(68%) had no bleeding. 
 
 
 
 
  
16
34
Present Absent
BLEEDING
61 
  
 
 
 
ABDOMINAL PAIN NUMBER 
Present 11(22%) 
Absent 39(78%) 
 
 
 In this study abdominal pain was present in (22%) and absent in 78% 
of cases 
 
 
 
22%
78%
ABDOMINAL PAIN
Present Absent
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ALOC NUMBER 
Present 45(90%) 
Absent 5(10%) 
 
 
 In this study 90% of the cases had altered level of consciousness and 
10% of cases did not have altered level of consciousness 
 
 
 
  
45
5
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BLOOD PRESSURE NUMBER 
>90 24(48%) 
<90 26(52%) 
 
 In this study, 24(48(%) had blood pressure >90 mm Hg and 26(52%) 
had blood pressure <90 mm Hg. 
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ICTERUS NUMBER 
Present 21(42%) 
Absent 29(58%) 
 
In this study, 21(42%) had icterus and 29(58%) didn’t have jaundice. 
 
 
 
  
21
29
Present Absent
ICTERUS
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FREE FLUID NUMBER 
Present 10(20%) 
Absent 40(80%) 
 
 In this study, 10 (20%) had free fluid detected by clinical 
examination.40 (80%) didn’t have free fluid . 
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CRP NUMBER 
Positive 30(60%) 
Negative 20(40%) 
 
In this study, CRP was positive in 30(60 %)  and negative in 
20(40%). 
 
 
  
60%
40%
CRP
Positive Negative
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S.No Variable 
Outcome Chi square test (C)/ 
Fisher exact test (F) 
P value Improved Death 
1. Diagnosis  
Drug 
induced 3 12(80%) 
0.455 (F) 
Autoimmune 2 1(33%) 
Infection 5 12(70%) 
Metabolic 2 1(33%) 
Congestive 1 3(75%) 
Inconclusive 3 5(62%) 
 
 In this study, among the causes drug induced had mortality of 80% 
followed by congestive(75%) infection (70%) inconclusive (62%) 
autoimmune (33%) metabolic(33%) P  value was 0.4 so there was no 
association etiology and outcome. 
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Association between bleeding and outcome 
 
S.No Variable 
Outcome Chi square test / Fisher 
exact test 
P value Improved Death 
2. Bleeding 
Present 5 11 
0.93 (C) 
Absent 7 27 
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Association between duration of illness and outcome  
 
S.No Variable 
Outcome Chi square test / Fisher 
exact test 
P value 
Improved Death 
3. 
Duration 
of illness 
<1 
week 
13 26 
1.00 (F) 
>1 
week 
3 8 
 
In this duration of illness  was compared to the outcome.in cases with 
illness <1 week 26 cases died and 13 cases improved while in cases with 
illness >1 week 8 cases died and 3 improved.the P value was 1 hence there 
was no association between duration of illness and outcome 
 
 
13
3
26
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<1 week >1 week
DURATION OF ILLNESS & oUTCOME
IMPROVED DEATH
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Association between PT and outcome 
 
S.No Variable 
Outcome Chi square test / Fisher 
exact test 
P value Improved Death 
4. SGPT 
>1000 11 20 
0.50 (C) 
<1000 5 14 
 
 
 In this study SGPT value was compared with the outcome in cases 
with value <1000  twenty cases died while 11 cases  improved.In cases with 
values >1000 14 cases died and 5 cases improved.The P value was 0.5 
hence there was no correlation between SGPT values and outcome. 
 
 
 
  
11
5
20
14
0
5
10
15
20
25
>1000 <1000
SGPT vs OUTCOME
IMPROVED DEATH
71 
  
 
Prothrombin time NUMBER 
<40 33(66%) 
>40 17(34%) 
 
 In this study, prothrombin time was <40 in 33(66%) and was <40 in 
17(34%). 
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APTT NUMBER 
<40 18(36%) 
>40 32(64%) 
 
 
In this study, APTT was <40 in 18(36%) and >40 32(64%). 
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INR NUMBER 
>2 29(58%) 
<2 21(42%) 
 
In this study, INR was >2 in 29(58%) and INR was <2 in 21(42%). 
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SGOT NUMBER 
>1000 28(56%) 
<1000 22(44%) 
 
 In this study, SGOT was >1000 in 28(56%) and SGOT was <1000 in 
22 (44%). 
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SGPT NUMBER 
>1000 31(62%) 
<1000 19(38%) 
 
 In this study, liver enzyme SGPT was >1000 in 31(62%) and SGPT 
was <1000 in 19(38%). 
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UREA NUMBER 
>40 24(48%) 
<40 26(52%) 
 
In this study, 24(48%) had urea >40 and 26(52%) had urea <40. 
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CREATININE NUMBER 
<3.5 47(94%) 
>3.5 3(6%) 
 
In this study, 47(94%) had creatinine <3.5 and 3(6%) had creatinine >3.5. 
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DISCUSSION 
 
AGE DISTRIBUTION  
             In this study among the 50 children studied the age distribution was found 
to  be 42% of the children belong to 6-12 years, 36% belong to 1-5  years and 
22% belong to <1 year group. This is comparable to kaur et al70 in which   41.8% 
belong to 6-12 years  ;44% belong to 1-5 years and 14% belong to <1 year In  
S Ganguly et al73   age ranged from 2.8 to 12 years with mean age of 7.12 years 
  
SEX DISTRIBUTION 
 In our  study the sex distribution of acute liver failure was found to be 
30(60%) of the children  are females and 20(40%) are males. This is comparable 
to kaur et al70 70% are males 30% are females 
 
ETIOLOGICAL PROFILE 
In this study, out of the 50 children studied, 16(32%) improved and 
34(68%)  died. In this study, the etiology of liver failure  was found to be 
infection(34%), drug induced(30%), idiopathic(16%), congestive causes(8%). 
 
 This is comparable to kaur et al 70in which Infections were the most 
common cause  (77%) with viral hepatitis (hepatitis A-E) in 72% cases. This is 
comparable to this study pediatric acute liver failure study group71 in which 
etiology of acute liver failure  in infants are found to be inderminate 
(38%),neonatal hemochromatosis(13.6%),herpes simplex virus (12.8%) 
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spontaneous survival occurred in 60% of infants  16% underwent liver 
transplantation and 24% died without undergoing liver transplantation71  
 
 O’Grady et al 73 argued for viruses other than hepatitis A and Bas bad 
prognostic markers, they documented that hepatitis E had the highest rate of 
mortality, the overall survival of ALF due to viral hepatitis was 40% while it was 
25% for non A non B hepatitis in this study. Also khuroo et al74   depicted that non 
E viral hepatitis as a predictor of poor outcome. 
 
DURATION OF ILLNESS 
 In this study the duration of illness was found to be <1 week in (78%) and 
>1 week in (22%). 
 
CLINICAL CORRELATION 
 In this study, 16(32%) had  high coloured urine and 34(68%) didn’t have 
high coloured urine. 
 
 In this study, 16(32%) had bleeding and 34(68%) had no bleeding. This is 
 comparable to kaur et al70 which 42% had bleeding and 58% did not have 
bleeding. In this study abdominal pain was present in  (22%) and absent in 78% of 
cases In this study 90% of the cases had altered level of  consciousness and 10% 
of cases did not have altered level of consciousness 
 
 In this study, 24(48(%) had blood pressure >90 mm Hg and 26(52%) had 
blood pressure <90 mm Hg. In this study, 21(42%) had icterus and 29(58%) 
didn’t have  jaundice. 
80 
  
 
 In this study, 10 (20%) had free fluid detected by clinical examination.40 
(80%) didn’t  have free fluid. In this study, CRP was positive in 30(60 %)  and 
negative in 20(40%).  
 
ETIOLOGICAL PROFILE AND OUTCOME 
 In this study, among the causes in drug induced 12 cases died 3 improved 
in infection  12 died 5 improved among autoimmune I died 2 improved among 
metabolic 2 cases improved 1 died among congestive causes 3 died and 1 
improved and among inconclusive 5 cases died and 3 cases improved.P  value was 
0.4 so there was no association etiology and outcome .this is comparable to  
 
DURATION OF ILLNESS AND OUTCOME 
 In this duration of illness  was compared to the outcome.in cases with 
illness <1 week 26 cases died and 13 cases improved while in cases with illness 
>1 week 8 cases died and 3 improved.the P value was 1 hence there was no 
association between duration of illness and outcome In this study SGPT value was 
compared with the outcome in cases with value <1000  twenty cases died while 11 
cases  improved. In cases with values >1000 14 cases died and 5 cases improved. 
The P value was 0.5 hence there was no correlation between SGPT values and 
outcome. 
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LABORATORY  
 In this study, prothrombin time was <40 in 33(66%) and was <40 in 
17(34%). In this study, 47(54%) had creatinine >3.5 and 3(6%) had creatinine 
<3.5. In this study, 24(48%) had urea >40 and 26(52%) had urea <40 In this 
study, liver enzyme SGPT was >1000 in 31(62%) and SGPT was <1000 in 
19(38%). In this study, SGOT was >1000 in 28(56%) and SGOT was <1000 in 22 
(44%). In this study, INR  was >2 in 29(58%) and INR was <2 in 21(42%). This 
may be comparable with this study Etiology outcome and prognostic indicators of 
childhood fulminant hepatic liver failure in United kingdom72which found with an 
INR of 4 or more the mortality rate reaches 86% with an INR of <4 mortality is as 
low as 27%. 
 
 In this study, APTT was <40 in 18(36%) and >40 32(64%). In this study, 
prothrombin time was <40 in 33(66%) and was <40 in 17(34%). 
 
  
Conclusion 
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CONCLUSION 
 
1. In this study infection(34%) was the most common cause of acute liver 
failure followed by drug (30%) 
 
2. In this study out of the 50 cases studied 68% died and 32% improved 
 
3. Highest mortality was in the drug (80%) and congestive etiology(75%)  
 
4. There was no correlation between demographic factors such as age sex 
and outcome 
 
5. Our study failed to  establish any association between clinical laboratory 
values and outcome 
 
 Since ALF is a potentially fatal condition, estimating the likelihood of 
spontaneous recovery and identifying patients who cannot be salvaged without 
liver transplantation is necessary. Prognostic factors that predict mortality and 
need for early liver transplantation are required. Our study results highlight the 
fact that viral hepatitis remains the most common cause of acute liver failure. 
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Place of study: INSTITUTE OF CHILD HEALTH AND HOSPITAL FOR CHILDREN,  
Name of Investigator :  .DR. VAANMATHI.A.S 
Name of Participant    age:   sex:  
Address:      Hospital No:  RC   No: 
We are conducting a study on CLINICAL PROFILE AND ETIOLOGY OF ACUTE 
LIVER FAILURE IN CHILDREN 
We request you to participate in the study 
 The purpose of this study is to find out the clinical profile and etiology of acute liver failure in 
children in our centre,ICH&HC  
• To study clinical profile correlate with various etiology 
• Clinical course, various complications & outcomes of acute liver failure in children can be 
studied. This will help us to inform the parents about the prognosis & treatment response. 
 
 • The privacy of the patients in the research will be maintained throughout the study. In the event of 
any publication or presentation resulting from the research, no personally identifiable information will 
be shared. 
• Taking part in this study is voluntary. You are free to decide whether to participate in this study or to 
withdraw at any time; your decision will not result in any loss of benefits to which you are otherwise 
entitled. 
. 
 
 
 
Signature of investigator                                        Signature of participant’s Father / Guardian 
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PROFORMA 
 
NAME    : 
AGE     : 
PLACE    : 
IP NO     : 
DURATION OF ILLNESS : 
FEVER    : 
JAUNDICE    : 
ABDOMINAL PAIN  : 
HIGH COLOURED URINE : 
BLEED    : 
ALOC    : 
VITALS    : 
HR :                   BP  :  
LIVER SPAN   : 
FREE FLUID   : 
SPLEEN    : 
COMA SCALE   : 
HB     : 
TOTAL COUNT   : 
DIFFERENTIAL COUNT  : 
PERIPHERAL SMEAR  : 
LFT     : 
OT     : 
PT     : 
PT/APTT/INR   : 
TOTAL PROTEIN/ALBUMIN/GLOBULIN : 
USG ABDOMEN   : 
CXR     : 
SERUM CERULOPLASMIN : 
KF RING    : 
SERUM PARACETAMOL LEVELS : 
UREA/CREATININE  : 
 SERUM SODIUM/POTASSIUM : 
OTHER INVESTIGATIONS : 
TREATMENT   : 
 
name outcome diagnosis address age age/sex ip no duration fever jaundice
high 
colored u
aloc bleed
abdminal 
pain
drug sensorium bp pulse icterus liver s/c spleen ff hb ps tc dc crp pt
devesh improved inconclusive vandavasi 8 months  male 937227 7 days 2 days present no yes 2 days no no no e4 v3m4 90/60 140 present 12cm firm 6cm present 10.6 10300 57/43 negative no coagulation
jaffrin 
fathima
improved
paracetamol 
toxicity
adayar 3  female 937818 5 days 5 days no no 2 days no no
paracetam
ol
letargic 98/70 100 no no no present 10.7 6370 67/33 positive 30.5/31/2.28
ankitha 
das
improved
autoimmune 
hepatitis
tripura 11 female 937024 4 days no 20 days no 3 days no  no no e3v3m5 110/70 90 present 10cm firm no no 12.5 9800 56/39/5 negative 36/42/3.43
aaron improved leptospirosis chennai 3  male 934786 1 day 1 day 1 day no 1 day hematuria no no e1vtm1 100/70 120 present 10cm firm 3cm no 3.2
features 
suggestive of 
hemolytic 
anemia
18300 62/31/7 positive 24.7/27.7/2.37
monalisa death
nerkundra
m
10  female 936072 2 days 2 days 2days no 2 days no no valproate e1vtm1 120/90 118 present 6cm soft no no 10  1600 67/23/10 negative 58.9/0.8/5.1
sibikashree death
paracetamol 
toxicity
vellore 2  female 925127 7 days 7 days 2 days 2 days 1day
hematemesis 1 
episodemalena 1 
episode
no
paracetam
ol
e1v1m4 96/62 130 present 5.5cmfirm no no 9.4 9399 70/19/11 positive 110/50.6/9.88
ajith death hepatitis A bihar 3  female 875887 1 month 4 days 1month 1 month 3 days no no
native 
medicatio
n
e1vtm1 100/70 96 present 8cm firm no no 7.7
moderate 
anispoikilocytosi
s platelet in 
single and good 
clumps
19400 64/36 positive 58.5/78.6/4.5
lakshana death sepsis vellore 2  female 880577 10 days 10 days 7 days 7 days 1 day no no
native 
medicatio
n
e2v1m4 100/70 120 present 8cm firm no no 12.2 36000 66/34 positive 38/36.6/3.2
dinesh 
kumar
death inconclusive kadappa 2  male 921613 3 weeks 3 weeks 2 weeks 2 weeks 5 days no no no e1vtm1 90/60 130 present 10cm firm no no 7.9 8100 71/22/07 negative
>120/>120 inr 
5.2
ashwin death
paracetamol 
toxicity
kk nagar 6  male 925435 6 days 6 days no no 1 day
hematemesis 1 
episodemalena 1 
episode
no
paracetam
ol 
110mg/kg
e1vtm1 100/70 130 no 8cm firm no no 9.5 11300 81/14/0 negative 13.2/47.8/2.59
pooja death inconclusive vyasarpadi 6  female 928793 10 days 10 days 10 days 2 days 2 days no no
native 
medicatio
n
e2v3m4 100/70 120 present 9cm firm no no 10
netrophillia with 
hypersegmented 
neurophils
19400 85/9/6 positive 27.6/29/2.72
sahasara death
autoimmune 
hepatitis
choolaime
du
2  female 884515 1 month no 1 month 1 month 4 days no no no e2v1m4 90/60 110 present 7cm firm no no 6.4
anemia with 
thrombocytopen
ia
9600 71/21/8 positive 41/36/4.5
MASTER CHART
shaek 
amrin
improved drug induced
andhra 
pradhesh
5 female 937255 20 days 10 days 6 days 6 days 6 days hematuria no
adriamycin 
vincristine 
cyclophosp
hamide
e4v2m 100/60 110 present 8cm firm no no 5.7 4000 93/6/1 negative 100/42/9
b/o 
lakshmi
death tyrosinemia
andhra 
pradhesh
3 months  male 938302 9 days no 9 days 9 days 7 days
malena  1 
episode
no no e4v2m5 90/50 140 present 7cn firm 8cm firm no 9.3
normoctic 
normochromic 
anemia with 
thrombocytopen
ia
3300 39/59/11 positive 22.7/70/2
munihema
varshini
death PFIC
andhra 
pradhesh
2 female 922107 15 days 2 days 15 days 15 days 2 days no no no e1vtm1 110/70 160 present 7cmfirm no present 12
hypochromic 
anisocytosis 
platelet in single 
clumps
21200 56/39/5 positive 17.6/47.8/1.53
annaporan
i
death sepsis thanjavur 11  female 932092 2 days no 2 days 2 days 2 daays no no no e1vtm1 120/90 130 present 11cm firm 4cm no 7.2
moderate 
anispoikilocytosi
s platelet in 
single and good 
clumps
17500 67/26/6 positive 26.4/36.8/2
anbarasi improved sle salem 9  female 937120 20 days 20 days 4 days no 2 days no 3 da
azathiopri
ne
e3v3m5 100/70 110 no
7cm 
normal
no no 12.8
microcytic 
hypochromic 
anemia
11300 87/10/3 positive 83.4/56/7.07
jeyarani death
paracetamol 
toxicity
chennai 1  female 937792 7 days 7 days no no 1 day
hematemesis 1 
episode
no
paracetam
ol
e1vtm1 74/42 150 no 7cm firm no no 9.4 2800 32/68 positive 62/49/1.59
sivasakthi death
wilson/hepatit
is A
kallakurich
i
9  male 939585 3 days 3 days 3 days 3 days 1 day hematuria 3 days no e1vtm1 130/60 130 present 12cm firm 2cm present 3.6 39500 76/20/4 negative 26/44/3.3
muthuselv
am
improved
congestive 
hepatic 
failiure/hepati
tis B
kumbakon
am
9  male 939331 5 days no 4 days no no no 5 days no e3v3m5 90/60 100 present 10cm firm no no 8.2 24500 85/15 positive 39.1/34/3.31
thanuja 
barla
death
congestive 
hepatic 
failiure
andhra 
pradhesh
10  female 940777 1 week ni no no 3 days no no no e4v3m3 92/46 110 no 8cm firm no present 6.1 22700 60/40 negative 40/68/3
daniel death
paracetamol 
toxicity
chennai 1 male 942877 4 days 4 days no no 1 day hematemesis no
paracetmo
l
e1vtm1 130/90 100 no 9cm firm no no 5.3 8100 76/21/3 positive 85/48/11.5
thugilan death
paracetamol 
toxicity
kanchipura
m
6 months male 942762 3 days 3 days no no 1 day no no
paracetam
ol
e1vtm1 90/50 140 no 9cm firm no present 5.6 2600 35/4/11 positive 26.2/29.3/2.56
abiju improved dengue chennai 9  male 943230 7days 7 days 3 days 1 day no no no no e1vtm1 90/50 120 no 8cm soft no no 9.5
mild hypo mild 
anisocytosis
16400 83/10/7 positive 21.7/29.3/1.79
kaviyapriy
a
death
paracetamol 
toxicity
 arani 6 female 942324 3 days no no 1 day no no
paracetam
ol
e1vtm1 110/70 139 no 8cm soft np present 10.1
mild hypo mild 
anisocytosis
positive 12.6/43/6.48
yasika death dengue thiruvallur 2  female 944422 5 days 5 days no no 3 days no no no e1vtmi 80/50 130 present 8cm firm no present 9.6
mild hypo mild 
anisocytosis
26700 50/44/6 positive
37.2/no 
coagulation/2.
76
kavinaya death thiruvallur 6  female 946488 2 days 1 day no no 1 day
hematemesis4 
episodes
3 days no e1vtm1 80/40 138 no 6,5cm firm no no
surendar death
paracetamol 
toxicity
chennai 7  male 944898 4 days 4 days no no 1 day no 3 days
paracetam
ol
e3v3m5 120/80 120 no 7cm soft no no 8.7 6600 62/34/4 positie 34/54/1.8
yathiran death inconclusive thiruvarur 2  male 948422 7 days 7 days 7 days no 5 days NO No no e4v3m6 100/70 115 yes 8cm soft no no 9.4
moderate 
anispoikilocytosi
s platelet in 
single and good 
clumps
16000 75/17/8 positive 50.4/no/4.49
roobesh 
kumar
improved
congestive 
hepatic 
failiure
vellore 12  male 948437 6 days 6 days no no 2 days no no no e4v5m5 80/50 110 no 8cm firm no no 11.3 22600 83/10/7 negative 19.3/40.2/1.6
ragini death
rat killer 
poisoning
kanchipura
m
5  female 948938 no no no no 1 day hematemesis no
rat killer 
poison
e1vtm1 80/50 140 no 7cm soft no no 10.8
moderate 
anispoikilocytosi
s platelet in 
single and good 
clumps
6800  71/20/9 negative 160/90/9
sreenathi death inconclusive arani 3  male 94970 5days 5 days no no 1 day no no e1vtmi 90/60 110 no 7cm soft no no 7.4
severe to 
moderate 
hypochromic 
aniso 
poikilocytosis 
platelet in 
clumps
8400 50/34/16 positive 23/46/1.8
benson improved dengue chennai 1  male 951528 4 days 4 days no no 1day no no no e4v5m5 80/60 160 no 9cm soft no present 9.9 18300 33/6/11 positive 21/39,4/1.78
masquad 
asan
improved hepatitis A chennai 12  male 951598 8 days 8 days 7 days 7days 1 day hematemesis 7 days no e4v3m6 110/70 100 present 8cm soft no no 10.2 9500 60/31/9 positive 12.6/54/1.54
tejasri improved inconclusive vellore 2 female 951576 3 days 3 days no no 2 days no no no e4v3m4 80/50 120 no 10cmsoft no no 11.3 7800 50/44/6 positive  43/68/1.68
karthiga death sepsis
thiruvanna
malai
1  female 950799 5 days 5 days no no 2 days hematemesis no no e1vtm1 60/40 130 no 8cm soft no no 8 36400 86/14 negative 32.1/68.7/2.88
ijayasarath
i
improved
dengue/leptos
pirosis
chennai 9  male 950223 5days 5 days no no no hematuria no no e4v3m4 110/80 70 no 8cm soft no no 10.6 3800 46/41/13 negative 13.9/36/1.53
nisha death dengue chennai 5 female 949924 4 days 4 days no no 2 days no no no e1vtm1 70/60 100 no 7cm soft no no 13.6 11700 70/30 positive 38/46/1.98
sujatha death dengue chennai 10 female 950374 5 days 5 days no no 2 days no 1 day no e3v4m4 90/60 140 no 9cm soft no no 10.9 10200 53/47 negative 34/54/1.7
roshan death
paracetamol 
toxicity
chennai 4 male 952202 4 days 2 days no no 3 days no 1 day
paracetam
ol
e1vtm3 70/50 140 no 9 cm firm no no 12.7 15700 82/18 positive 45/68/6.8
rudhresh death dengue
kanchipura
m
4 male 953281 5 days 5 days no no 1 day hematemisis 3 days no e1vtm3 60/30 160 no 10 cm soft no no 6.5 23000 47/65/29 negative 42/58/4.2
jayamurug
an
death
paracetamol 
toxicity
vellore 10 male 946927 3 days 3 days 3 days 2 days 1 day no 3 days
paracetam
ol
e1vtm2 110/60 110 no 8 cm soft no no 7.2 7300 60/34/6 positive 20/47/16
samshika death
paracetamol 
toxicity
chennai 11 months female 942137 3 days 3 days 2 days no 1 day no no
paracetam
ol
e4vtm5 70/40 140 present 9cm soft no no 5.8 17700 80/20 positive
11.2/111/no 
coaglation
monisha death inconclusive krishnagiri 2 female 950769 20 days 20 days 3 days no 3 days no no no e2v3m4 90/60 180 no 12cm firm
spleen tip 
palpable
present 7.5 23300 75/25 positive 15.9/34.1/1.62
kavishri death dengue chennai 1 female 934968 5 days 5 days 5 days 2 days 2 days no no no e1vtm1 100/80 110 no 8 cm firm
spleen tip 
palpable
no 8.6 2500 34/47/19 negative 45/62/2.2
nivedhan improved metabolic thiruvallur 3 months male 952354 7 days no 7 days 3 days 7 days
hematemesis 
malena
no no e3v5m5 90/60 140 present 8 cm firm
spleen tip 
palpable
no 8 21200 66/31/3 negative 102.1/28.7/6.9
kenisha death dengue chennai 9 female 952804 7 days 7 days no no 2 days hematemisis 2 days no e1vtm1 90/70 140 12 cm firm no no 12.7 34200 79/17/4 negative 21.7/12.2/1.86
madhuvan
thani
improved
paracetamol 
toxicity
chennai 8 months female 948451 7 days 7 days no no 1 day no no
paracetam
ol
e3v4m5 90/60 120 no 6.5 soft no no 11.1 9500 61/39/2 positive 32/48/1.58
vaideki death dengue chennai 12 female 948934 5 days 5 days no no no no no no e1vtm1 100/70 120 7 cm soft no no 10.1 7500 70/30 negative 44/56/2.2
charulatha improved hepatitis A chennai 9 female 950346 5 days 5 days no no no no no no e3v5m5 70/40 130 8cm soft no no 11 8500 84/16 negative 24/43/1.6
tbr/dbr ot pt sap protien al sg abd
viral 
markers
wilson kf ring
cerla 
plasmin
treatment xray other
s 
paracetam
ol
duration 
of stay
urea creatinine sodium pottasium
5/2.7 268 164
4.1/2.6/1.
5
hepatomegaly increased echoes spleen 
normal 
negative no no
oxygen hepatic fluid vitamink 
syruplactulose ijection 
ampicillin tablet udca tab 
spironolactone
right 
pleural 
fluid
triglycerserum amylase10 serum 
lipase 44ide 1820 dengue igm 
negative,serum ammonia 58 
22 0.5 136 4
1.5/1.4 6700 4300 4.7/2.9 hepatomegaly mild free fluid abdomen no
oxygen hepatic fluid,injection 
n-acetyl cystiene,inj.vitam 
k,tab udca
7 17 0.6 137 3.2
11.2/9 1028 958 325 4.2/2.4 liver coarse increased echoes,no free fluid negative no no 19
hepatic fluid inj.vitamin k 
lactulose,inj 
pantoprazole,tab udca ffp 
transfusion,inj.methylprednis
olone
normal
anca positiveLKM antibody ANA 
positive cmv negative DCT 
positive ant SMA negative
25 0.7 145 4
10.7/0.7 223 33 129 5.6/3.6/2
hepatomegaly,reactive gb wall edema no 
ff spleen 8cm
negative no
mechanical ventilation 
hepatic fluid crystalline 
penicillninj. artesunatePRBC 
transfusion,vitamin k syrup 
lactulose,n acetyl cysteine 
infusion
normal
LDH 2280 CPK 20307 QBC 
negative Retic count 4% MSAT 
4+
76 0.5 132 5.1
20/8.3 748 1108 421 5.7/3.2 positive no
mechanical ventilation 
hepatic fluid adrenaline 
infusion,vancomycin,amikaci
n,vitamin k syrup lactulose,n 
acetyl cysteine infusion
blood culture pseudomonas 
scrub typhus 
negative,leptospirosis negative
15 0.5 168 2.5
4/1.6 15900 7882 5.1/3.6 hepatomegaly no freefluid no no
oxygen,inj.cefotaxim,inj.n 
acetylcysteine,syrup 
lactulose,inj.vitamink 
inj.pantoprazole FFP 
transfusion
16 60 1.3 172 4.6
22/8.9 652 433
5.9/3.3/2.
6
hepatomegaly reactive cholecystitis portal 
radicals appear prominent mild 
spleenomegaly minimal freee fluid 
abdomen
HAV 
positive
no no 40
mechanical ventillation 
hepatic fluid FFP transfusion 
tablet udca 
inj.ampicillin,inj.dopamine 
inj.ranitidine
cardiomeg
aly 
congestion
MAT positive widal negative,NEC 
no growth,
17 0.5 136 4.4
11.7/6 907 2028 389 5.1/3./1.6
mild hepatomegaly liver echoes diffusely 
altered spleen normal no free fluid
negative no
hepatic fluid inj.vitamin k 
lactulose,inj 
pantoprazole,tab udca ffp 
transfusion,inj.n acetyl 
cystine,inj.mannitol
normal
ammonia 483,lactate 1011,cpk 
119
30 0.5 140 5.4
18.5/7.8 403 572 5.7/3.8
thickened edematous Gbwall ?secondary 
to acute viral hepatitis
negative no
mechanical ventillation 
hepatic fluid FFP transfusion 
tablet udca 
inj.ampicillin,inj.dopamine 
inj.ranitidine
bilateral 
hyperinflat
ion
MAT negative NEC no growth 14 0.4 145 3.7
2.6/1.4 14486 6312 6.2/4/2.2
heoatomegaly increased echoes spleen 
normal no free fluid 
negative
mechanical ventillation 
hepatic fluid FFP transfusion 
tablet udca 
inj.ampicillin,inj.dopamine 
inj.ranitidine inj. N acetyl 
cystiene
normal
scrub typhus negative,dengue 
igM negative
,serum 
acetamino
phen 
46.9(10-
30)
112 2.1 141 3.3
4.4/2 4370 3020 49/2.8/2.1 normal study negative 27
oxygen hepatic fluid vitamink 
syruplactulose ijection 
ampicillin tablet udca inj.n 
acetylcystiene,FFP 
transfusion
cardiomeg
aly 
congestion
NEC klebsiella grown 97 2.4 132 4.7
18.7/8.2 294 192 384 6/3/2003
liver shows corse teture surface nodular 
multiple hyperechoic nodules on right 
lobe spleen normal
negative 45 oxygen 
suggestive 
of ARDS
Anti LKM ab positive , MAT DFM 
positive
34 0.6 145 2.4
5.3/3 6792 2093 107 3/1.5/1.5
rhabdomyosarcoma bladder liver normal 
spleen normal minimal free fluid 
abdomen
negative no
oxygen hepatic fluid inj.n 
acetyl cystine 
inj.pantoprazole FFP 
transfusion inj.dopamine,tab 
UDCA
98 1.6 133 4
6.1/4.9 4138 1448 200
4.8/2.9/1.
1
liver 9cm enlrged  in size altered 
echotexture GB partially distented Gbwall 
edema noted spleen 9.5cm enlarged mild 
free fluid portal vein 7mm
negative no oxygen normal
lactate 9.9 ammonia105 GGT 29 
alpha fetoprotein 125
53 0.4 143 3.1
13.6/6.5 105 39 5/2.7/2.3
hepatomegaly gall bladder wall 
thickrening moderate ascites mild 
spleenomegaly 
negative
mechanical ventilation 
hepatic fluid dopamine 
cefotaxim ffp vitamin k
cardiomeg
aly 
congestion
widAL NEGATIVE MSAT 
NEGATIVE liver biopsy 
progressive familial intrahepatic 
cholestasis
52 0.8 145 4.2
9.8/4.5 74 39
  
7.1/3.6/2.
5
hepatomegaly increased echoes spleen 
12cm no free fluid portal vein 0.8 cm 
negative
mechanical ventilation 
hepatic fluid  udca lactulose
normal
dct negative ammonia59 LDH 
981
2 DAYS 42 1 166 4.2
<1 38230 664
4.6/2.7/1.
9
hepatomegaly minimal free fluid no 
pleural fluid
negative
inj piptaz syrup lactulose tab 
udca inj vitamin k ffp tab 
prednisolone inj acyclovir
normal
ANA speckled 3+ anti ds DNA 
positive 
15 0.3 136 3.6
<1 14645 8250
5.6/3.8/1.
8
hepatomegaly no freefluid negative
mechanical ventilation inj 
nacetyl cystine dopamine 
oseltamivir
left lower 
lobe 
pneumoni
a
80 0.8 138 4.4
39.3/13 135 300
5.9/3.8/2.
1
liver echoes normal spleenomegaly ascites negative yes present 22 mechanical venti;lation normal 24 hor rinary copper 274 5 days 97 1.2 136 5.1
5.6/2.3 58 386
4.8/2.6/2.
2
ascites right kidney 8.8cm grade 1 rpd left 
kidney 8.6cm sleen normal
hbsag 
positive
33
dobutamine inj cefotaxim 
syrup lactulose tab udca 
metronidazole carnitine
cardiomeg
aly
echo severe LV dysfunction 
dilaed cardiomyopathy
114 1.4 128 2.4
4.1/2.1 224 120
5.5/2.9/2.
6
congestive hepatomegaly minimal ascites negative no no
dobutamine inj cefotaxim 
syrup lactulose tab udca 
metronidazole carnitine
cardiomeg
aly
echo severe LV dysfunction 
dilaed cardiomyopathy
36 1 128 4.4
1.4/0.6 11826 6936 5/3.5/1.5
hepatomegaly liver echoes increased gb 
wall edema
no no
mechanical ventilation 
dopamine adrenaline n 
acetyl cystine vitamin k 
pantoprazole ffp prbc 
26 61 0.8 125 5.8
1.2/0.8 3879 4817
4.1/3.6/0.
5
hepatomegaly free fluid no no
mechanical ventilation 
dopamine adrenaline n 
acetyl cystine vitamin k 
pantoprazole ffp prbc 
normal 38 104 1.5 153 5.3
<1 1977 1947 5.4/2.9 hepatomegaly minimal free fluid negative no m
cardiomeg
aly right 
pleural 
fluid
dengue positive mat negative
3.1/2 >10,000 5419 4.5/2.6
hepatomegaly reactive gb wall edema free 
fluid present
negative no
mechanical ventilation 
adrenalne dopamine ffp 
ceftrioxone azithromycin 
vitamin k
normal 58 84 3.8 144 5.4
2.9/0.6 683 2832 4/2.9/1.1
hepatomegaly reactive gb wall edema free 
fluid present
negative no
mechanical ventilation 
adrenalne dopamine ffp 
ceftrioxone azithromycin 
vitamin k
bilateral 
pleural 
fluid
lactate 92 cpk 70 ldh 728 5 days 43 0.8 132 4.7
<1 2418 422
5.4/3.6/1.
8
hepatomegaly gb wall edema no pleural 
fluid
negative no no
mechnical ventillation 
dopamine ffp hepatic fluid
bilateral 
pleural 
fluid
DFM Negative MAT negative 
scrub negative
3.3 16 0.7 128 3.6
2.1/0.6 137 435 333
4.3/2.9/1.
6
features suggestive of hepatitis no 
spleenomegaly no ascites
negative no no
udca viatamin k hepatic fluid 
lactulose enema
normal
lactate 6.7 ldh 1068 ammonia 41 
alpha fetoprotein 26
7 days 17 0.5 137 4.2
<1/ 492 754 6/3.2 hepatomegaly no free fluid negative no no
udca viatamin k hepatic fluid 
lactulose enema
normal echo severe MR severe AR RHD  6 days 60 1.2 132 4.3
4.8/2.5 6095 2427
5.4/3.8/1.
8
mild hepatomega;y no free fluid negative no no
mechnical ventillation 
dopamine ffp hepatic fluid
normal 1 day 44 2.3 132 2.5
2.9/1.6 8813 2024 5/3.4/1.6 hepatomegaly no freefluid
hepatitis A 
positive
no no
mechnical ventillation 
dopamine ffp hepatic fluid
normal MAT positive 5 days 97 3.9 135 5.2
<1 1588 541
5.4/2.9/2.
3
mild hepatomegaly gall bladder wall 
edema right pleural fluid no free fluid 
abdomen
negative n o no
mechnical ventillation 
dopamine ffp hepatic fluid
normal dengue positive 4 days 18 0.5 135 4.5
9.9/3.3 786 982
7.1/3.8/3.
3
liver normal spleen normal no free fluid
hepatitis A 
positive 
no no
hepatic fluid tab udca 
inj.vitamin k lactulose syrup
normal widal negative 8 days 15 0.6 135 5.1
<1 7745 5752 203 4.8/2.8/2
mild hepatomegaly o free fluid no pleural 
fluid
no no
hepatic fluid tab udca 
inj.vitamin k lactulose syrup
pneumonit
is both 
lower lobe
MAT negative denguenegative 3 days 18 0.6 132 4.6
<1 366 119 4.7/3.3.1.4 mild hepatomegaly no free fluid negative no no
mechnical ventillation 
dopamine ffp hepatic fluid
normal lactate 115  5days 132 2.7 145 6.1
<1 138 99
3.7/2.8/0.
7
mild hepatomegaly gall bladder wall 
edema right pleural fluid no free fluid 
abdomen
negative no no
hepatic fluid tab udca 
inj.vitamin k lactulose syrup
bilateral 
pleural 
fluid
DFM positive dengue positive 5 days 16 0.4 138 3.5
<1 234 333
<1 2063 698
4.4/3.5/0.
5
16300 6600 183
4.7/2.6/2.
1
hepatomegaly negative no no hepatic fluid tab
pneumonit
is R lower 
lobe
37 5 days 28 1 112 4.6
<1 1865 466 43/2.5/1.8 hepatomegaly no free fluid negative no no
Right 
pleural 
fluid
igM dengue positive 5 days 58 0.6 131 4.3
11.1/4.4 350 250 28
4.5/2.8/1.
7
hepatomegaly moderate  free flid hepatitis A no no normal 177 3.2 140 4.2
8.7/4.4 247 650 166 4/2.9/1.1 hepatomegaly no free fluid negative no no
pulmonary 
congestion
42 14 0.6 132 3.9
3-Aug 352 152
5.2/2.8/2.
4
hepatomegaly minimal free flid negative no no normal 20 days 76 1.6 158 6.5
2.8/1.2 112 46 2.8/1.2 hepatomegaly negative no no normal 52 0.5 130 2.6
1.9/1.2 657 413
3.5/1.8/1.
7
hepatomegaly no free fluid negative no no normal 7 days 14 0.8 139 4.6
16.2/8.1 543 697
4.3/2.3/2.
2
hepatomegaly free fluid negative no no
bilateral 
pleral flid
209 3.6 138 4.1
<1 3249 2465 5.2/3.2/2
heoatomegaly increased echoes spleen 
normal no free fluid 
negative no no normal Ig 28 24 0.6 129 5.1
<1 233 433 hepatomegaly negative no no normal 28 0.5 133 4.3
2.2 233 122 hepatomegaly negative no no normal 32 0.8 134 4.2
